Generer rapport
Nordic Biotech Opportunity Fund K/S
Strandvejen 125, c/o NB Capital ApS, 2900 Hellerup, CVR 31262488
Branche: Ventureselskaber og kapitalfonde
Virksomhedsform
Kommanditselskab
Etableret
2008
Størrelse
Mikro
Ansatte
-
Omsætning
-
DKK
Bruttofortj.
-
DKK
Primært resultat (EBIT)
-38.867.000
DKK
Årets resultat
-38.875.000
DKK
Egenkapital
22
MDKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
368/383
"Bund 10%"
Rang i Danmark
342.590/344.121
"Bund 10%"
Direktion top 3
- Nordic Biotech General Partner Aps | Direktør |
Legale ejere top 3
33.33-49.99% | European Investment Fund | LU |
15-19.99% | Danmarks Eksport- og Investeringsfond | DK |
15-19.99% | Foundation Asset Management AB | SE |
Tegningsregler
Virksomheden tegnes af komplementaren.
Stamoplysninger baseret på CVR
Navn | Nordic Biotech Opportunity Fund K/S |
CVR | 31262488 |
Adresse | Strandvejen 125, c/o NB Capital ApS, 2900 Hellerup |
Branche | Ventureselskaber og kapitalfonde [643040] |
Etableret | 07-02-2008 (16 år) |
Første regnskabsperiode | 31-01-2008 til 31-12-2008 |
Virksomhedsform | Kommanditselskab |
Antal ansatte | - |
Reklamebeskyttelse | Nej |
Revisor | Deloitte Statsautoriseret Revisionspartnerselskab siden 12-06-2023 |
Regnskabsperiode | 01-01 til 31-12 |
Vedtægter seneste | 27-05-2014 |
Medlem af brancherne
- Ventureselskaber og kapitalfondeNACE6 indeholdende 502 virk.
- Investeringsforeninger, investeringsselskaber o.l.NACE3 indeholdende 8.700 virk.
- Pengeinstitut- og finansieringsvirksomhed undtagen forsikring og NACE2 indeholdende 149.422 virk.
- Pengeinstitut- og finansvirksomhed, forsikringNACE1 indeholdende 152.415 virk.
Formål
Virksomhedens formål er at investere i (i) Osteologix, Inc., 425 Market Street, Suite 2230, San Francisco, Ca 94105, USA, (ii) Gastrotech Pharma A/S, Nyhavn 43B, 1051 København K, (iii) Forward Pharma A/S, Nyhavn 43B, 1051 København K, og (iv) Biotica Technology Ltd., Chesterford Research Park, Little Chesterford, Nr Saffron Walden, Essex, UK CB10 IXL, idet selskabet dog - betinget af forudgående skriftligt samtykke fra selskabet investeringskomite - må investere i andre enheder, når en sådan investering er en del af en selskabsretlig omstruktering, som involverer forretningen eller aktiviteterne i en eller flere af selskaberne nævnt under (i)-(iv) ovenfor.
Regnskab
2022 | 2021 | 2020 | |
---|---|---|---|
Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
Omsætning | - - | - - | - - |
Bruttofortjeneste | - - | - - | - - |
Årets resultat | -38.875 - | -5.233 - | -1.138 - |
Egenkapital | 21.764 -64% | 60.639 -8% | 65.872 -2% |
Balance | 21.822 -64% | 60.705 -8% | 65.939 -2% |
Ledelsesberetning
Management's review
Financial reviewThe income statement for 2022 shows a loss of DKK 38,875 thousand against a loss of DKK 5,233 thousand last year, and the balance sheet at 31 December 2022 shows equity of DKK 21,756 thousand.The activities for the year are significantly impacted by the negative fair value adjustment of the Limited Partnership’s investment in Forward Pharma A/S amounting to DKK 38,752 thousand.OperationsNordic Biotech General Partner ApS participates in the Limited Partnership as a general partner and manages the Limited Partnership in this capacity. Further, the Limited Partnership has concluded an advisory agreement with Nordic Biotech Advisors ApS pursuant to which Nordic Biotech Advisors ApS attends to the daily operation of the Limited Partnership.InvestmentsForward Pharma A/SForward Pharma is a Danish biopharmaceutical company that commenced development in 2005 of FP187®, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. Forward Pharma granted to Biogen an irrevocable license to all of its IP through the Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017.Rose Pharma IncIn connection with the final dissolution of Rose Pharma A/S the Limited Partnership received shares in NV Rose LLC, a company incorporated and domiciled in Bermuda. These shares were subsequently exchanged for shares in Rose Pharma Inc, a company incorporated and domiciled in the United States. The activities of Rose Pharma Inc comprise the development of a medical product that will improve the lives of irritable bowel syndrome sufferers by developing targeted treatments for acute pain.
Financial reviewThe income statement for 2022 shows a loss of DKK 38,875 thousand against a loss of DKK 5,233 thousand last year, and the balance sheet at 31 December 2022 shows equity of DKK 21,756 thousand.The activities for the year are significantly impacted by the negative fair value adjustment of the Limited Partnership’s investment in Forward Pharma A/S amounting to DKK 38,752 thousand.OperationsNordic Biotech General Partner ApS participates in the Limited Partnership as a general partner and manages the Limited Partnership in this capacity. Further, the Limited Partnership has concluded an advisory agreement with Nordic Biotech Advisors ApS pursuant to which Nordic Biotech Advisors ApS attends to the daily operation of the Limited Partnership.InvestmentsForward Pharma A/SForward Pharma is a Danish biopharmaceutical company that commenced development in 2005 of FP187®, a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. Forward Pharma granted to Biogen an irrevocable license to all of its IP through the Settlement and License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017.Rose Pharma IncIn connection with the final dissolution of Rose Pharma A/S the Limited Partnership received shares in NV Rose LLC, a company incorporated and domiciled in Bermuda. These shares were subsequently exchanged for shares in Rose Pharma Inc, a company incorporated and domiciled in the United States. The activities of Rose Pharma Inc comprise the development of a medical product that will improve the lives of irritable bowel syndrome sufferers by developing targeted treatments for acute pain.
12-06-2023